Loading...

Jupiter Neurosciences, Inc.

JUNS•NASDAQ
Healthcare
Biotechnology
$1.02
$0.00(0.00%)

Jupiter Neurosciences, Inc. (JUNS) Stock Overview

Explore Jupiter Neurosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.3/100

Key Financials

Market Cap33.4M
P/E Ratio-9.76
EPS (TTM)$-0.11
ROE3.45%
Fundamental Analysis

AI Price Forecasts

1 Week$0.86
1 Month$1.08
3 Months$1.60
1 Year Target$6.42

JUNS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Jupiter Neurosciences, Inc. (JUNS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $6.42.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -9.76 and a market capitalization of 33.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
0.00%
Profit Growth
$-0.10
↑ 49.001%
EPS Growth
$-0.10
↑ 43.47%
Operating Margin
0.00%
↑ 20.14%
ROE
344.69%
↑ 49.001%
Dividend Yield
0.00%
Analyst Recommendations data is not available for JUNSAnalyst Recommendations details for JUNS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

CEO

Christer Rosen

Employees

4

Headquarters

1001 North US HWY 1, Jupiter, FL

Founded

2022

Frequently Asked Questions

;